FINDINGS OF SCIENTIFIC MISCONDUCT NIH GUIDE, Volume 24, Number 40, November 24, 1995 P.T. 34 Keywords: Ethics/Values in Science & Technol Grants Administration/Policy+ Department of Health and Human Services Notice is hereby given that the Office of Research Integrity (ORI) has made final findings of scientific misconduct in the following case: Nicholas Y. Lorenzo, M.D., Mayo Foundation: On October 16, 1995, ORI found that Nicholas Y. Lorenzo, M.D., formerly of the Mayo Foundation, committed scientific misconduct by falsifying and fabricating data incorporated in an abstract submitted for presentation at a professional meeting; the research was supported by a Public Health Service (PHS) grant. Dr. Lorenzo has entered into a Voluntary Exclusion Agreement with ORI in which he has accepted ORI\'s finding and has agreed to exclude himself voluntarily, for the three year period beginning October 16, 1995, from: (1) any contracting or subcontracting with any agency of the United States Government and from eligibility for, or involvement in, nonprocurement transactions (e.g., grants and cooperative agreements) of the United States Government, as defined in 45 CFR Part 76 and 48 CFR Subparts 9.4 and 309.4 (Debarment Regulations); and (2) serving in any advisory capacity to PHS, including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant. The above voluntary exclusion, however, shall not apply to Dr. Lorenzo\'s future training or practice of clinical medicine whether as a medical student, resident, fellow, or licensed practitioner unless that practice involves research or research training. The abstract was withdrawn prior to publication, and thus, no correction of the literature is required. Weishu Y. Weiser, Ph.D., Harvard Medical School: On October 19, 1995, ORI found that Weishu Y. Weiser, Ph.D., formerly of the Harvard Medical School at Brigham and Women\'s Hospital, committed scientific misconduct by falsifying data in biomedical research supported by two Public Health Service (PHS) grants. Dr. Weiser has entered into a Voluntary Exclusion Agreement with ORI in which she has accepted ORI\'s finding and has agreed to exclude herself voluntarily, for the three year period beginning October 19, 1995, from: (1) participating in any Federal contracts or subcontracts and from eligibility for or involvement in Federal nonprocurement transactions (e.g., grants and cooperative agreements), as covered in 45 CFR Part 76 and 48 CFR Subparts 9.4 and 309.4 (Debarment Regulations); and (2) serving in any advisory capacity to PHS, including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant. She has agreed to submit a letter to the Journal of Immunology and to the Proceedings of the National Academy of Sciences to retract the articles entitled \"Human recombinant migration inhibitory factor activates human macrophages to kill Leishmania donovani\" (Journal of Immunology 147:2006-2011, 1991), \"Recombinant migration inhibitory factor induces nitric oxide synthase in murine macrophages\" (Journal of Immunology 150:1908-1912, 1993), and \"Recombinant human migration inhibitory factor has adjuvant activity\" (Proceedings of the National Academy of Sciences 89:8049-8052, 1992). INQUIRIES For further information contact: Director, Division of Research Investigations Office of Research Integrity 5515 Security Lane, Suite 700 Rockville, MD 20852 Telephone: (301) 443-5330 .
